|
 |
|
Maxter |
| As the face of Lupin in the critical care segment and Anti-Infectives, Maxter Division emulates the Company’s objective of ‘saving more lives’. As a spin-off from Endeavour, the division was launched in 2006-07. The inception of Maxter has empowered Lupin to tap unexplored opportunities in chosen therapeutic area, with an unwavering focus. This division focuses on giving the best therapeutic care in the critical care segment. It reaches out to interventionists and super-specialty doctors and has also ventured into the field of wound management.
Key Products : Maxter
|
Product |
Therapeutic segment |
Product Rank in the relevant segment |
|
Merotrol |
Meropenem |
1 |
|
Tazar |
Piperacillin + Tazobactam |
1 |
|
Ceff |
Cephalexin Oral Solids
|
3 |
|
Cetil |
Cefuroxime Oral Solids
|
5 |
|
Cefantral |
Cefotaxime Injectibles |
9 |
| |
